You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

IFEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ifex, and what generic alternatives are available?

Ifex is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in IFEX is ifosfamide; mesna. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ifosfamide; mesna profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for IFEX?
  • What are the global sales for IFEX?
  • What is Average Wholesale Price for IFEX?
Summary for IFEX
Drug patent expirations by year for IFEX
Drug Prices for IFEX

See drug prices for IFEX

Pharmacology for IFEX
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity

US Patents and Regulatory Information for IFEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-001 Dec 30, 1988 AP RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-004 Oct 10, 1992 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 AP RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-003 Oct 10, 1992 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IFEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-001 Dec 30, 1988 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-001 Dec 30, 1988 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for IFEX

See the table below for patents covering IFEX around the world.

Country Patent Number Title Estimated Expiration
Czech Republic 284584 Injekční roztoky mesny (STABILIZATION PROCESS OF SODIUM-2-MERCAPTOETHANE SUFONATE INJECTION SOLUTION) ⤷  Sign Up
Denmark 0591710 ⤷  Sign Up
Australia 4888393 ⤷  Sign Up
Japan H06263629 MESNA INJECTION, ITS PREPARATION, AND MEDICINE MADE OF IT FOR INHIBITING OXYAZAPHOSPHORINE ADVERSE REACTION ⤷  Sign Up
Finland 48602 ⤷  Sign Up
Japan S54101432 DETOXICATION OF CELL PROPAGATION CONTROLLING AGENT ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.